Bausch + Lomb Corporation and AcuFocus, Inc announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus, according to a press release.
The FDA approved the IC-8 Apthera intraocular lens for the treatment of cataracts in July 2022. It is the first and only non-toric extended depth of focus intraocular lens (IOL) approved for patients who have as much as 1.5 diopters (D) of corneal astigmatism.
“Bausch + Lomb is a legacy name in eye care with a fully integrated portfolio of offerings in eye health,” said Al Waterhouse, president and CEO, AcuFocus in the press release. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
Read the full press release here.
Related Content
